Literature DB >> 1394360

Thrombosis of the popliteal vein.

H E Schmitt1, M J Mihatsch.   

Abstract

Among 3,307 consecutive patients (3,556 legs) with deep venous thrombosis, 54 (1.5%) showed an isolated thrombus of the popliteal vein on phlebography. The majority of those had a history of "effort" or long lasting flexion during air or bus travel. Forty-four percent suffered from pulmonary embolism as the first sign of deep venous thrombosis. Functional phlebography demonstrated the primary site of thrombosis at folds forming in the vein wall at flexion. In order to further elucidate the pathogenetic mechanism, 158 popliteal veins were examined phlebographically in different functional states revealing age-related characteristic wall patterns of rings and folds in flexion causing transient impairment of flow. Complementary morphological studies of 120 popliteal veins during autopsy showed a transverse rippling of the vein wall caused by intimal fibrosis and partial atrophy of the media corresponding to the phlebographic findings. It is concluded that microtrauma during effort in combination with impaired venous backflow and fibrotic transformation of the venous wall can lead to thrombus formation in the popliteal vein.

Entities:  

Mesh:

Year:  1992        PMID: 1394360     DOI: 10.1007/bf02733929

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  3 in total

1.  Sudden natural deaths associated with commercial air travel.

Authors:  R Sarvesvaran
Journal:  Med Sci Law       Date:  1986-01       Impact factor: 1.266

2.  Air travel and thrombotic episodes: the economy class syndrome.

Authors:  J M Cruickshank; R Gorlin; B Jennett
Journal:  Lancet       Date:  1988-08-27       Impact factor: 79.321

3.  Peripheral venous aneurysms with recurrent pulmonary embolism: report of a case and review of the literature.

Authors:  L H Greenwood; J M Yrizarry; J W Hallett
Journal:  Cardiovasc Intervent Radiol       Date:  1982       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.